Human Longevity, Inc. and LEV Foundation announced a strategic collaboration to investigate biological drivers of exceptional longevity. The partnership will analyze blood samples from centenarians and supercentenarians, combining HLI’s AI-driven precision longevity platform with LEVF’s mission to extend healthy human lifespan.
The project will conduct comprehensive multi-omic analyses, including genomics and proteomics, to identify biomarkers and pathways associated with exceptional longevity and to compare molecular features of extremely long-lived individuals with broader population cohorts.
Both Natalie S. Coles-de Grey and LEVF President and Chief Science Officer Aubrey de Grey, Ph.D., are joining HLI’s scientific advisory board. The company claims findings could inform the development of diagnostics, therapeutics and preventive strategies aimed at extending healthspan and may lay the groundwork for future longitudinal studies.
Human Longevity, Inc. was founded in 2013 and integrates genomics, artificial intelligence and multimodal diagnostics, while LEV Foundation, founded in 2022, is a California 501(c)(3) nonprofit focused on research to extend healthy human lifespan.
